SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Nygren Peter) "

Sökning: WFRF:(Nygren Peter)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
11.
  •  
12.
  • Daskalakis, Kosmas, et al. (författare)
  • <em>Ex vivo </em>activity of cytotoxic drugs and targeted agents in Small Intestinal NETs
  • ????
  • Annan publikation (övrigt vetenskapligt)abstract
    • <p><strong>Introduction: </strong>Small Intestinal Neuroendocrine Tumours (SI-NET) are considered to be generally resistant to systemic treatment. To date predictive markers for drug activity are lacking.</p><p><strong>Patients and Methods: </strong>Tumour samples from 27 patients with SI-NET were analyzed <em>ex vivo</em> for sensitivity to a panel of cytotoxic drugs and targeted agents using a short-term total cell kill assay. Samples of renal cancer, colorectal cancer (CRC), ovarian cancer, and chronic lymphocytic leukemia (CLL) were included for comparison. For the SI-NET subset, drug sensitivity was analyzed in relation to clinico-pathological variables and pre-treatment biomarkers.</p><p><strong></strong><strong>Results: </strong>For standard cytotoxic drugs<strong>, </strong>SI-NETs demonstrated similar or higher sensitivity to 5-FU, platinums, gemcitabine and doxorubicin compared with CRC. For targeted kinase inhibitors, SI-NET was among the most sensitive diagnoses. CLL and ovarian cancer were generally the most sensitive diagnoses to both cytotoxic drugs and protein kinase inhibitors. The mTOR inhibitor sirolimus exhibited modest cytotoxic activity.</p><p>Individual SI-NET samples demonstrated great variability in <em>ex vivo </em>sensitivity for most drugs. Cross-resistance between different drugs also varied considerably, being higher among protein kinase inhibitors.</p><p>Age, stage, grade, peritoneal carcinomatosis and extra-abdominal metastases as well as serum chromogranin A and urine 5-HIAA concentrations at diagnosis did not correlate to drug sensitivity <em>ex vivo</em>.</p><p><strong>Conclusions: </strong>SI-NETs exhibit variable but generally intermediate sensitivity <em>ex vivo </em>to cytotoxic and targeted drugs. Clinico-pathological factors and currently used biomarkers were not clearly associated to <em>ex vivo</em> sensitivity, challenging these criteria for treatment decisions in SI-NETs. The great variability in drug sensitivity calls for individualized selection of therapy.</p>
  •  
13.
  • Daskalakis, Kosmas, et al. (författare)
  • <em>Ex vivo</em> activity of cytotoxic drugs and targeted agents in small intestinal neuroendocrine tumors
  • 2018
  • Ingår i: Endocrine-Related Cancer. - 1351-0088 .- 1479-6821. ; 25:4, s. 471-480
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Small intestinal neuroendocrine tumors (SI-NETs) are generally considered resistant to systemic treatment. To date, predictive markers for drug activity are lacking. Tumor samples from 27 patients with SI-NETs were analyzed ex vivo for sensitivity to a panel of cytotoxic drugs and targeted agents using a short-term total cell kill assay. Samples of renal cancer, colorectal cancer (CRC), ovarian cancer and chronic lymphocytic leukemia (CLL) were included for comparison. For the SI-NET subset, drug sensitivity was analyzed in relation to clinicopathological variables and pre-treatment biomarkers. For cytotoxic drugs, SI-NETs demonstrated similar or higher sensitivity to 5-FU, platinum, gemcitabine and doxorubicin compared with CRC. For several of the targeted kinase inhibitors, SI-NET was among the most sensitive solid tumor types. CLL and ovarian cancer were generally the most sensitive tumor types to both cytotoxic drugs and protein kinase inhibitors. SI-NET was more sensitive to the mTOR inhibitor sirolimus than the other solid tumor types tested. Individual SI-NET samples demonstrated great variability in ex vivo sensitivity for most drugs. Cross-resistance between different drugs also varied considerably, being higher among protein kinase inhibitors. Age, stage, grade, peritoneal carcinomatosis and extra-abdominal metastases as well as serum chromogranin A and urine 5-HIAA concentrations at diagnosis did not correlate to drug sensitivity ex vivo. SI-NETs exhibit intermediate sensitivity ex vivo to cytotoxic and targeted drugs. Clinicopathological factors and currently used biomarkers are not clearly associated to ex vivo sensitivity, challenging these criteria for treatment decisions in SI-NET. The great variability in drug sensitivity calls for individualized selection of therapy.</p>
  •  
14.
  •  
15.
  • Fryknäs, Mårten, et al. (författare)
  • Iron chelators target both proliferating and quiescent cancer cells
  • 2016
  • Ingår i: Scientific Reports. - NATURE PUBLISHING GROUP. - 2045-2322 .- 2045-2322. ; 6
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Poorly vascularized areas of solid tumors contain quiescent cell populations that are resistant to cell cycle-active cancer drugs. The compound VLX600 was recently identified to target quiescent tumor cells and to inhibit mitochondrial respiration. We here performed gene expression analysis in order to characterize the cellular response to VLX600. The compound-specific signature of VLX600 revealed a striking similarity to signatures generated by compounds known to chelate iron. Validation experiments including addition of ferrous and ferric iron in excess, EXAFS measurements, and structure activity relationship analyses showed that VLX600 chelates iron and supported the hypothesis that the biological effects of this compound is due to iron chelation. Compounds that chelate iron possess anti-cancer activity, an effect largely attributed to inhibition of ribonucleotide reductase in proliferating cells. Here we show that iron chelators decrease mitochondrial energy production, an effect poorly tolerated by metabolically stressed tumor cells. These pleiotropic features make iron chelators an attractive option for the treatment of solid tumors containing heterogeneous populations of proliferating and quiescent cells.</p>
  •  
16.
  • Fryknäs, Mårten, et al. (författare)
  • Iron chelators target both proliferating and quiescent cancer cells
  • 2016
  • Ingår i: Scientific Reports. - 2045-2322 .- 2045-2322. ; 6
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Poorly vascularized areas of solid tumors contain quiescent cell populations that are resistant to cell cycle-active cancer drugs. The compound VLX600 was recently identified to target quiescent tumor cells and to inhibit mitochondrial respiration. We here performed gene expression analysis in order to characterize the cellular response to VLX600. The compound-specific signature of VLX600 revealed a striking similarity to signatures generated by compounds known to chelate iron. Validation experiments including addition of ferrous and ferric iron in excess, EXAFS measurements, and structure activity relationship analyses showed that VLX600 chelates iron and supported the hypothesis that the biological effects of this compound is due to iron chelation. Compounds that chelate iron possess anti-cancer activity, an effect largely attributed to inhibition of ribonucleotide reductase in proliferating cells. Here we show that iron chelators decrease mitochondrial energy production, an effect poorly tolerated by metabolically stressed tumor cells. These pleiotropic features make iron chelators an attractive option for the treatment of solid tumors containing heterogeneous populations of proliferating and quiescent cells.</p>
  •  
17.
  •  
18.
  • Glimelius, Bengt, et al. (författare)
  • U-CAN a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.
  • 2018
  • Ingår i: Acta Oncologica. - 0284-186X .- 1651-226X. ; 57:2, s. 187-194
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Background: Progress in cancer biomarker discovery is dependent on access to high-quality biological materials and high-resolution clinical data from the same cases. To overcome current limitations, a systematic prospective longitudinal sampling of multidisciplinary clinical data, blood and tissue from cancer patients was therefore initiated in 2010 by Uppsala and Umeå Universities and involving their corresponding University Hospitals, which are referral centers for one third of the Swedish population.</p><p>Material and Methods: Patients with cancer of selected types who are treated at one of the participating hospitals are eligible for inclusion. The healthcare-integrated sampling scheme encompasses clinical data, questionnaires, blood, fresh frozen and formalin-fixed paraffin-embedded tissue specimens, diagnostic slides and radiology bioimaging data.</p><p>Results: In this ongoing effort, 12,265 patients with brain tumors, breast cancers, colorectal cancers, gynecological cancers, hematological malignancies, lung cancers, neuroendocrine tumors or prostate cancers have been included until the end of 2016. From the 6914 patients included during the first five years, 98% were sampled for blood at diagnosis, 83% had paraffin-embedded and 58% had fresh frozen tissues collected. For Uppsala County, 55% of all cancer patients were included in the cohort.</p><p>Conclusions: Close collaboration between participating hospitals and universities enabled prospective, longitudinal biobanking of blood and tissues and collection of multidisciplinary clinical data from cancer patients in the U-CAN cohort. Here, we summarize the first five years of operations, present U-CAN as a highly valuable cohort that will contribute to enhanced cancer research and describe the procedures to access samples and data.</p>
  •  
19.
  • Glimelius, Bengt, et al. (författare)
  • U-CAN : a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden
  • 2018
  • Ingår i: Acta Oncologica. - Taylor & Francis Group. - 0284-186X .- 1651-226X. ; 57:2, s. 187-194
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Background: Progress in cancer biomarker discovery is dependent on access to high-quality biological materials and high-resolution clinical data from the same cases. To overcome current limitations, a systematic prospective longitudinal sampling of multidisciplinary clinical data, blood and tissue from cancer patients was therefore initiated in 2010 by Uppsala and Umea Universities and involving their corresponding University Hospitals, which are referral centers for one third of the Swedish population. Material and Methods: Patients with cancer of selected types who are treated at one of the participating hospitals are eligible for inclusion. The healthcare-integrated sampling scheme encompasses clinical data, questionnaires, blood, fresh frozen and formalin-fixed paraffin-embedded tissue specimens, diagnostic slides and radiology bioimaging data. Results: In this ongoing effort, 12,265 patients with brain tumors, breast cancers, colorectal cancers, gynecological cancers, hematological malignancies, lung cancers, neuroendocrine tumors or prostate cancers have been included until the end of 2016. From the 6914 patients included during the first five years, 98% were sampled for blood at diagnosis, 83% had paraffin-embedded and 58% had fresh frozen tissues collected. For Uppsala County, 55% of all cancer patients were included in the cohort. Conclusions: Close collaboration between participating hospitals and universities enabled prospective, longitudinal biobanking of blood and tissues and collection of multidisciplinary clinical data from cancer patients in the U-CAN cohort. Here, we summarize the first five years of operations, present U-CAN as a highly valuable cohort that will contribute to enhanced cancer research and describe the procedures to access samples and data.</p>
  •  
20.
  • Glimelius, Bengt, et al. (författare)
  • U-CAN a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden
  • 2018
  • Ingår i: Acta Oncologica. - Taylor & Francis. - 0284-186X .- 1651-226X. ; 57:2, s. 187-194
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Background: Progress in cancer biomarker discovery is dependent on access to high-quality biological materials and high-resolution clinical data from the same cases. To overcome current limitations, a systematic prospective longitudinal sampling of multidisciplinary clinical data, blood and tissue from cancer patients was therefore initiated in 2010 by Uppsala and Umea Universities and involving their corresponding University Hospitals, which are referral centers for one third of the Swedish population.</p><p>Material and Methods: Patients with cancer of selected types who are treated at one of the participating hospitals are eligible for inclusion. The healthcare-integrated sampling scheme encompasses clinical data, questionnaires, blood, fresh frozen and formalin-fixed paraffin-embedded tissue specimens, diagnostic slides and radiology bioimaging data.</p><p>Results: In this ongoing effort, 12,265 patients with brain tumors, breast cancers, colorectal cancers, gynecological cancers, hematological malignancies, lung cancers, neuroendocrine tumors or prostate cancers have been included until the end of 2016. From the 6914 patients included during the first five years, 98% were sampled for blood at diagnosis, 83% had paraffin-embedded and 58% had fresh frozen tissues collected. For Uppsala County, 55% of all cancer patients were included in the cohort.</p><p>Conclusions: Close collaboration between participating hospitals and universities enabled prospective, longitudinal biobanking of blood and tissues and collection of multidisciplinary clinical data from cancer patients in the U-CAN cohort. Here, we summarize the first five years of operations, present U-CAN as a highly valuable cohort that will contribute to enhanced cancer research and describe the procedures to access samples and data.</p>
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (52)
Typ av publikation
tidskriftsartikel (256)
annan publikation (18)
doktorsavhandling (16)
rapport (4)
bokkapitel (4)
forskningsöversikt (4)
visa fler...
konferensbidrag (3)
recension (2)
licentiatavhandling (1)
visa färre...
Typ av innehåll
refereegranskat (256)
övrigt vetenskapligt (71)
populärvet., debatt m.m. (1)
Författare/redaktör
Nygren, Peter, (221)
Larsson, Rolf, (136)
Gullbo, Joachim (48)
Fryknäs, Mårten, (34)
Glimelius, Bengt, (32)
Mahteme, Haile, (26)
visa fler...
Rickardson, Linda, (22)
Lindhagen, Elin (17)
Graf, Wilhelm, (16)
Senkowski, Wojciech, (15)
Wickström, Malin (14)
Dhar, Sumeer, (14)
Gustafsson, Mats, (12)
Linder, Stig (12)
Höglund, Martin, (12)
Nygren, Per-Åke, (11)
Nilsson, Peter, (10)
Lindman, Henrik, (10)
Lewensohn, Rolf (10)
Gustafsson, Mats G., (9)
Isaksson, Anders, (9)
Bergh, Jonas (8)
Nordin, Karin, (8)
Ehrsson, Hans (8)
Uhlén, Mathias, (7)
Zhang, Xiaonan (7)
Nilsson, Kenneth, (7)
Hellman, Per, (7)
Nygren, Jonas, (7)
Nygren, Ingela, (7)
Berglund, Åke, (7)
Nygren, Anders, (7)
Andersson, Claes (7)
Godskesen, Tove, (7)
Luthman, Kristina, (7)
Kihlbom, Ulrik, (7)
Liss, Per, (7)
Karlsson, Henning, (7)
Rosenquist, Richard (6)
Sundström, Christer (6)
Larsson, R (6)
Stålberg, Peter (6)
Thorell, Anders (6)
Johansson, Birgitta, ... (6)
Sjöblom, Tobias, (6)
Ehrsson, H (6)
Grundmark, Birgitta, (6)
Tholander, Bengt, (6)
Jarvius, Malin, (6)
Hansell, Peter, (6)
visa färre...
Lärosäte
Uppsala universitet (226)
Umeå universitet (16)
Kungliga Tekniska Högskolan (15)
Linköpings universitet (11)
Göteborgs universitet (8)
Lunds universitet (7)
visa fler...
Mittuniversitetet (6)
Chalmers tekniska högskola (5)
Karolinska Institutet (5)
Örebro universitet (4)
Stockholms universitet (2)
Högskolan i Gävle (2)
Ersta Sköndal Bräcke högskola (2)
Högskolan Kristianstad (1)
Mälardalens högskola (1)
Högskolan i Jönköping (1)
Högskolan i Halmstad (1)
Linnéuniversitetet (1)
Högskolan i Borås (1)
RISE (1)
visa färre...
Språk
Engelska (264)
Odefinierat språk (13)
Svenska (8)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (189)
Naturvetenskap (23)
Teknik (17)
Samhällsvetenskap (9)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy